Home › Liver Cancer (Hepatocellular Carcinoma) › Pennsylvania › Philadelphia
Liver Cancer (Hepatocellular Carcinoma) clinical trials in Philadelphia, PA
16 studies for Liver Cancer (Hepatocellular Carcinoma) are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #98, Philadelphia
National Liver Cancer Screening Trial
RecruitingPhase 4
- University of Pennsylvania, Philadelphia
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RecruitingPhase 3
- Research Site, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RecruitingPhase 1/2
- Children's Hospital of Philadelphia, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RecruitingPhase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi away
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi away
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Thomas Jefferson University, Philadelphia
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recruiting
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Y-90 Treatment Response Using Transarterial Radioembolization
RecruitingPhase 2
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
RecruitingPhase 1/2
- University of Pennsylvania, Philadelphia
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
RecruitingPhase 1/2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RecruitingPhase 2
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
SBRT With Atezo/Bev for HCC
RecruitingPhase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
RecruitingObservational study
- Thomas Jefferson Hospital, Philadelphia
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RecruitingPhase 4
- Albert Einstein Healthcare Network, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Philadelphia
Liver Cancer (Hepatocellular Carcinoma) trials in other cities
- Houston, TX31 studies
- New York City, NY24 studies
- Dallas, TX19 studies
- Los Angeles, CA19 studies
- Boston, MA18 studies
- Cleveland, OH18 studies
- Chicago, IL16 studies
- Pittsburgh, PA15 studies
- San Francisco, CA14 studies
- Orange, CA14 studies
- Jacksonville, FL14 studies
- San Antonio, TX13 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.